EPAS1 and nonpapillary renal cell carcinoma: Recent pharmaceutic outcomes in the VHL-HIF2α-angiogenesis pathway of ccRCC which based on specific molecular target drugs such as the inhibitor of receptor tyrosine kinases (RTKs) had changed the treatment landscape for patients with metastatic ccRCC [6, 7].